Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 289-301

  Ren, Song ^a   Kalhorn, Thomas F ^a   McDonald, George B ^a   Anasetti, Claudio ^a   Appelbaum, Frederick R ^a   Slattery, John T ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4 OXOCYCLOPHOSPHAMIDE; ALDEHYDE DEHYDROGENASE; CYCLOPHOSPHAMIDE; DESCHLOROETHYL CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DROPERIDOL; DRUG METABOLITE; FLUCONAZOLE; LORAZEPAM; ONDANSETRON; PHOSPHORAMIDE MUSTARD; PHOSPHORAMIDIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MICHAELIS CONSTANT; NAUSEA; PRIORITY JOURNAL; VOMITING;

ALDEHYDE DEHYDROGENASE; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; ERYTHROCYTES; HUMANS; HYDROXYLATION; IMMUNOSUPPRESSIVE AGENTS; TIME FACTORS;

EID: 0031657664     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90178-3     Document Type: Article

References (24)

1. Sladek NE. Metabolism and pharmacokinetics of cyclophosphamide and related oxazaphosphorines. In: Powis G, editor. Anticancer drugs: reactive metabolism and drug interactions. New York: Pergamon Press; 1994. p. 79-156.
2. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochrome P450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-37.
3. Bohnenstengel F, Hofman U, Eichelbaum M, Kroener HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996;51:279-301.
4. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-35.
5. Colvin M, Padgett CA, Fenselau CA. Biologically active metabolites of cyclophosphamide. Cancer Res 1973;33:915-8.
6. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolisms of cyclophosphamide and ifosphamide. Biochem Pharmacol 1974;23:115-29.
7. Struck RF, Kirk MC, Witt MH, Laster WR Jr. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 1975;2:46-52.
8. Bagley CM, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226-33.
9. D'Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, et al. Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer 1979;15:7-10.
10. Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, McLean AE. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 1983;10:192-3.
11. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 1980;64:1061-6.
12. Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987;20:248-52.
13. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Bucker CD, Bensinger WI, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-94.
14. Takamizawa A, Matsumoto S, Iwata T, Tochino Y, Katagiri K, Yamaguchi K, et al. Studies on cyclophosphamide metabolites and their related compounds; II: preparation of an active species of cyclophosphamide and related compounds. J Med Chem 1975;18:376-83.
15. Friedman OM, Boger E, Grubliauskas V, Sommer H. Synthesis of N-phosphorylated derivatives of nitrogen mustards with latent cytotoxicity. J Med Chem 1963;6:50-8.
16. Bradford MA. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
17. Mathewson K, Record CO. Erythrocyte aldehyde dehydrogenase activity in alcoholic subjects and its value as a marker for hepatic aldehyde dehydrogenase in subjects with and without liver disease. Clin Sci 1986;70:295-9.
18. Sladek E, Powers JF, Grage GM. Half-life of oxaphosphorines in biological fluids. Drug Metab Dispos 1984;12:553-9.
19. Chen TL, Kennedy MJ, Anderson LW, Kiraly SB, Black KC, Colvin OM, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/ aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997;25:544-51.
20. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997;15:1885-96.
21. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992;10:995-1000.
22. Chang TKH, Yu L, Maurel P, Waxman D J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997;57:1946-54.
23. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-69.
24. Agarwal DP, Cohn P, Goedde HW, Hempel J. Aldehyde dehydrogenase from human erythrocytes: structural relationship to the liver cytosolic isozyme. Enzyme 1989; 42:47-52.